InVivo tanks on push-back for spinal injury trial

Tue, 08/27/2013 - 4:05pm
Mass Device

InVivo shares lose nearly half their value after the company announces a delay to its spinal treatment clinical trials.

InVivo tanks on push-back for spinal injury trial

InVivo Therapeutics (OTC:NVIV) announced a push-back on its time-lines for enrollment in a clinical trial examining its spinal cord injury treatment, a move that brought NVIV shares down by nearly half today.

InVivo announced that, under the terms of its FDA investigational device exemption, each trial patient must be followed for 3 months and the company must win agency approval before enrolling the next, meaning it will take InVivo an estimated 21 months to enroll its 5 patients.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.